NASDAQ:BWAY BrainsWay (BWAY) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free BWAY Stock Alerts $5.29 +0.04 (+0.76%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$5.24▼$5.4150-Day Range$5.25▼$7.1452-Week Range$1.38▼$7.61Volume65,521 shsAverage Volume139,261 shsMarket Capitalization$88.03 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get BrainsWay alerts: Email Address BrainsWay MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside32.3% Upside$7.00 Price TargetShort InterestHealthy0.67% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.71Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.02) to $0.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.86 out of 5 starsMedical Sector497th out of 938 stocksSurgical & Medical Instruments Industry56th out of 95 stocks 3.3 Analyst's Opinion Consensus RatingBrainsWay has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, BrainsWay has a forecasted upside of 32.3% from its current price of $5.29.Amount of Analyst CoverageBrainsWay has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.67% of the outstanding shares of BrainsWay have been sold short.Short Interest Ratio / Days to CoverBrainsWay has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BrainsWay has recently decreased by 41.26%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBrainsWay does not currently pay a dividend.Dividend GrowthBrainsWay does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BWAY. Previous Next 3.2 News and Social Media Coverage News SentimentBrainsWay has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for BrainsWay this week, compared to 1 article on an average week.Search Interest4 people have searched for BWAY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows13 people have added BrainsWay to their MarketBeat watchlist in the last 30 days. This is an increase of 44% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BrainsWay insiders have not sold or bought any company stock.Percentage Held by Insiders19.00% of the stock of BrainsWay is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.11% of the stock of BrainsWay is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BrainsWay are expected to grow in the coming year, from ($0.02) to $0.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BrainsWay is -40.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BrainsWay is -40.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBrainsWay has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About BrainsWay Stock (NASDAQ:BWAY)Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, the Asia Pacific, Europe, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.Read More BWAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BWAY Stock News HeadlinesMarch 28, 2024 | finance.yahoo.comBrainsWay Announces Positive Results in Late-Life Depression Post-Marketing AnalysisMarch 23, 2024 | americanbankingnews.comHead-To-Head Analysis: InspireMD (NYSE:NSPR) vs. BrainsWay (NASDAQ:BWAY)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 18, 2024 | finance.yahoo.comBrainsWay Broadens Partnership with Katie’s Way Plus Through Order of an Additional 18 Deep TMS™ SystemsMarch 18, 2024 | globenewswire.comBrainsWay Broadens Partnership with Katie's Way Plus Through Order of an Additional 18 Deep TMS™ SystemsMarch 17, 2024 | investorplace.comLow-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck WithMarch 11, 2024 | markets.businessinsider.comBuy Rating and Raised Price Target for Brainsway Reflecting Strong Financial Growth and Expansion PotentialMarch 8, 2024 | seekingalpha.comBrainsWay Ltd. (BWAY) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 6, 2024 | msn.comBrainsway beats top-line and bottom-line estimates; initiates FY24 outlookMarch 6, 2024 | benzinga.com2BWAY : BrainsWay Earnings PreviewMarch 6, 2024 | investorplace.comBWAY Stock Earnings: BrainsWay Beats Revenue for Q4 2023March 6, 2024 | globenewswire.comBrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational HighlightsFebruary 27, 2024 | seekingalpha.comBrainsWay Q4 Earnings PreviewFebruary 21, 2024 | finance.yahoo.comBrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024February 21, 2024 | globenewswire.comBrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024January 16, 2024 | finance.yahoo.comZacks.com featured highlights VirTra, Universal Stainless & Alloy, Carrols Restaurant, BrainsWay and VircoJanuary 11, 2024 | benzinga.comBrainsWay Stock (NASDAQ:BWAY) Dividends: History, Yield and DatesJanuary 10, 2024 | finance.yahoo.comBrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” TechnologyJanuary 3, 2024 | finance.yahoo.comRecent Price Trend in Brainsway Ltd. Sponsored ADR (BWAY) is Your Friend, Here's WhyJanuary 2, 2024 | finance.yahoo.comBest Momentum Stocks to Buy for January 2ndJanuary 1, 2024 | msn.comAnalysts Think This Small-Cap Stock Could Soar in 2024December 27, 2023 | finance.yahoo.comDoes Brainsway Ltd. Sponsored ADR (BWAY) Have the Potential to Rally 48.15% as Wall Street Analysts Expect?December 19, 2023 | finance.yahoo.comBrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. NetworkDecember 14, 2023 | finance.yahoo.comBrainsway Ltd. Sponsored ADR (BWAY) Is a Great Choice for 'Trend' Investors, Here's WhyDecember 11, 2023 | markets.businessinsider.comBuy Rating on Brainsway: Growth and Expansion in South Korea with Net Income-Positive OutlookDecember 11, 2023 | finance.yahoo.comWall Street Analysts Predict a 68.72% Upside in Brainsway Ltd. Sponsored ADR (BWAY): Here's What You Should KnowSee More Headlines Receive BWAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BrainsWay and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today3/29/2024Next Earnings (Estimated)5/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:BWAY CUSIPN/A CIK1505065 Webwww.brainsway.com Phone(722) 582-4030FaxN/AEmployees134Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$12.00 Low Stock Price Target$3.00 Potential Upside/Downside+32.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,200,000.00 Net Margins-13.20% Pretax Margin-12.41% Return on Equity-10.05% Return on Assets-6.88% Debt Debt-to-Equity RatioN/A Current Ratio5.68 Quick Ratio5.30 Sales & Book Value Annual Sales$31.78 million Price / Sales2.77 Cash FlowN/A Price / Cash FlowN/A Book Value$2.50 per share Price / Book2.12Miscellaneous Outstanding Shares16,640,000Free Float13,476,000Market Cap$88.03 million OptionableNot Optionable Beta1.22 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Hadar Levy (Age 50)Chief Executive Officer Comp: $470.16kMr. Avner Hagai (Age 68)Founder & Director Comp: $47.37kProf. Abraham Zangen (Age 54)Co-Founder, Member of Scientific Advisory Board & Director Comp: $77.2kMr. Christopher J. Boyer Ph.D. (Age 46)Vice President of Global Marketing Comp: $337.95kDr. Yiftach Roth Ph.D. (Age 53)Founder & Chief Scientific Officer Comp: $108kMr. Ido MaromChief Financial OfficerMr. Menachem C. Klein Esq.VP, General Counsel & Corporate SecretaryDr. Aron TendlerChief Medical OfficerMore ExecutivesKey CompetitorsAllurion TechnologiesNYSE:ALURBlueRiver AcquisitionNYSE:BLUAKORU Medical SystemsNASDAQ:KRMDDelcath SystemsNASDAQ:DCTHenVVeno MedicalNASDAQ:NVNOView All CompetitorsInstitutional OwnershipQuadrature Capital LtdBought 10,761 shares on 3/25/2024Ownership: 0.065%Tucker Asset Management LLCBought 5,145 shares on 3/4/2024Ownership: 0.033%Barclays PLCBought 37,715 shares on 2/15/2024Ownership: 0.227%Citadel Advisors LLCBought 26,414 shares on 2/15/2024Ownership: 0.159%Quadrature Capital LtdBought 10,761 shares on 2/14/2024Ownership: 0.065%View All Institutional Transactions BWAY Stock Analysis - Frequently Asked Questions Should I buy or sell BrainsWay stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BrainsWay in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BWAY shares. View BWAY analyst ratings or view top-rated stocks. What is BrainsWay's stock price target for 2024? 3 equities research analysts have issued 12 month price targets for BrainsWay's shares. Their BWAY share price targets range from $3.00 to $12.00. On average, they predict the company's share price to reach $7.00 in the next year. This suggests a possible upside of 32.3% from the stock's current price. View analysts price targets for BWAY or view top-rated stocks among Wall Street analysts. How have BWAY shares performed in 2024? BrainsWay's stock was trading at $6.48 at the start of the year. Since then, BWAY shares have decreased by 18.4% and is now trading at $5.29. View the best growth stocks for 2024 here. Are investors shorting BrainsWay? BrainsWay saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 111,600 shares, a decline of 41.3% from the February 29th total of 190,000 shares. Based on an average daily trading volume, of 144,700 shares, the short-interest ratio is presently 0.8 days. View BrainsWay's Short Interest. When is BrainsWay's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024. View our BWAY earnings forecast. How were BrainsWay's earnings last quarter? BrainsWay Ltd. (NASDAQ:BWAY) posted its earnings results on Wednesday, March, 6th. The company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. The company earned $9.03 million during the quarter, compared to the consensus estimate of $8.40 million. BrainsWay had a negative net margin of 13.20% and a negative trailing twelve-month return on equity of 10.05%. During the same quarter in the prior year, the company earned ($0.12) EPS. What guidance has BrainsWay issued on next quarter's earnings? BrainsWay updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $37.0 million-$40.0 million, compared to the consensus revenue estimate of $35.7 million. What other stocks do shareholders of BrainsWay own? Based on aggregate information from My MarketBeat watchlists, some companies that other BrainsWay investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Pfizer (PFE), Neuronetics (STIM), Boingo Wireless (WIFI), Eastman Chemical (EMN), Enbridge (ENB) and Energy Transfer (ET). When did BrainsWay IPO? BrainsWay (BWAY) raised $30 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 2,500,000 shares at a price of $11.94 per share. Cantor acted as the underwriter for the IPO. Who are BrainsWay's major shareholders? BrainsWay's stock is owned by a number of retail and institutional investors. Top institutional shareholders include AIGH Capital Management LLC (6.25%), Worth Venture Partners LLC (1.56%), Essex Investment Management Co. LLC (1.42%), Legato Capital Management LLC (0.50%), Psagot Value Holdings Ltd. Israel (0.32%) and Barclays PLC (0.23%). How do I buy shares of BrainsWay? Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BWAY) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BrainsWay Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.